Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.
about
Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price settingIs a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysisChoosing quality of care measures based on the expected impact of improved care on health.A simulation model approach to analysis of the business case for eliminating health care disparities.Clinical management of BRCA1- and BRCA2-associated breast cancer.Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan.Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancerTumor gene expression profiling in women with breast cancer. Test category: prognostic.Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany.A breast cancer care report card. An assessment of performance and a pursuit of valueSocietal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.Statistical methods in cancer research.Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancerDecision analysis in medicine.Defining a high mortality risk group among women with primary breast cancerThe value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)Methods in comparative effectiveness research.Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trialAdjuvant chemotherapy in stage I breast cancer. More harm than benefit.Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities.Adjuvant therapy of node-negative breast cancer.Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.Systemic adjuvant therapy of breast cancer.What Patients Can Tell Us: Topic Analysis for Social Media on Breast Cancer.Chemotherapy for solid tumoursAdjuvant chemotherapy for node-negative breast cancer.The costs and benefits of a screening program to detect dementia in older drivers.Lifetime cost-effectiveness analysis of intraoperative radiation therapy versus external beam radiation therapy for early stage breast cancer.Serotonin transporter polymorphism, depressive symptoms, and emotional impulsivity among advanced breast cancer patients.Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.Trade-offs Between Efficacy and Cardiac Toxicity of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients: Do Competing Risks Matter?Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?Inaccuracies in estimates of life expectancies of patients with bronchial cancer in clinical decision making.Pharmacoeconomics of Cancer Therapy.Side effects of adjuvant chemotherapy: perceptions of node-negative breast cancer patients.Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.Life expectancy estimation with breast cancer: bias of the declining exponential function and an alternative to its use.Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals.Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan.Radiofrequency ablation plus nucleotide analogous for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis
P2860
Q30886036-7C824DD9-119C-4F6C-9D1C-CFE4A9E75CC5Q33599906-482B803E-71CB-4092-AA7C-3794AEBCB212Q33725005-5EFF14D6-518C-4F32-A9FE-17EB6EF6D2C1Q33850319-E7059F50-5F48-489C-9FEE-B5E89E307BEEQ33915589-5D21104A-B4E5-45EF-A221-2C86A314BB5FQ34008690-B75BB777-376F-4D2C-BD56-295CF701313CQ34022200-1C2351AA-4619-4EBD-AD12-A7C327014752Q34130881-A6F6E9D3-9D02-4F9D-94F7-AAD4793F17E0Q34140072-9A9975EE-4B41-4696-97F8-5F1185E747FBQ34185786-0F137A22-6611-42FE-92B0-D00A257AD565Q34196301-76F8C1F7-47CF-4D7A-97EF-58CDFFB06BF8Q34199563-401E9FB6-960C-4909-B125-A8E843E5D7EDQ35776211-4DBD3CA0-BC6B-4091-B663-DA99B3F92B2AQ35821389-133220E8-44FD-41D0-BE11-345323614055Q35978238-2BF32F7E-5A69-446C-82DD-AE9F5CED6B06Q36364504-8003328D-F929-4EE9-84D8-218A20FE6192Q36417734-5D5FE623-6D7A-47A3-A67E-92E9E02078C9Q36614123-DC709B4C-0B6C-44FE-9F76-C29D5687BDE3Q36652809-25BB20F3-E2F2-44B7-AF87-C5735039FB37Q37477060-635DEEBB-2930-4452-861E-C55E4A6C9EA3Q40441763-1BAF6AEC-F1EA-4474-85A9-7948A1425C94Q40951867-12692A32-A241-449D-B453-2840C6D3AA33Q41360912-DAA06349-B57F-4B66-9A49-7779C93DD30AQ41390906-31FA6AEB-8E87-4F8C-8152-FBEC7F99C524Q42856634-7BD41128-5454-481C-BCEB-323C0B22EE12Q44084981-946F9C3A-F47A-452D-BDB5-78D4A498D4F6Q45084619-F4B90619-4A06-4615-A77E-20061AA18A30Q47159525-39E93443-755C-4B6E-9415-C9BC1A70FF11Q47287674-A2ACE0E3-F9D2-4F7F-BC9D-7A91D9517B57Q48065668-A23F71C1-611E-4666-9178-D1A5E93E0007Q48318138-BEFEE402-FF65-45E1-8FB1-001CFEB4628CQ50128272-A0B08128-814C-4F9B-A40B-9FC8FFB72F53Q50607562-EDC7129F-BEC3-4301-B03D-0A8457EE3DFBQ50658852-3EEBEC53-EC8C-4283-83B4-81E712D76752Q51102883-C7E12D57-FC8B-47A4-AB73-85E2649DFE06Q52604161-842CF8C3-F70C-4033-BD2E-2B58FBB67551Q52916019-B6D4EC95-65E6-4250-8E03-339ACC1E6E35Q53075352-36954283-A44F-4043-882B-5CF592E64BE0Q54531262-420A3AF6-8491-4423-B08D-6B596AC42BA4Q58776031-B11B9221-2D6B-439F-8ABF-CBC4C421781E
P2860
Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Efficacy and cost effectivenes ...... er. A decision-analysis model.
@en
Efficacy and cost effectivenes ...... er. A decision-analysis model.
@nl
type
label
Efficacy and cost effectivenes ...... er. A decision-analysis model.
@en
Efficacy and cost effectivenes ...... er. A decision-analysis model.
@nl
prefLabel
Efficacy and cost effectivenes ...... er. A decision-analysis model.
@en
Efficacy and cost effectivenes ...... er. A decision-analysis model.
@nl
P1476
Efficacy and cost effectivenes ...... er. A decision-analysis model.
@en
P2093
P304
P356
10.1056/NEJM199101173240305
P407
P577
1991-01-01T00:00:00Z